Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 128 entries
Sorted by: Best Match Show Resources per page
Treatment of pediatric multiple sclerosis.

Neuropediatrics

Kornek B.
PMID: 24203855
Neuropediatrics. 2013 Dec;44(6):309-13. doi: 10.1055/s-0033-1359308. Epub 2013 Nov 07.

Multiple sclerosis (MS) in children and adolescents has received increased attention during the past decade. Although not tested in randomized placebo-controlled trials, first-line disease-modifying therapies are widely used in patients with MS who are younger than 18 years. This...

Cite
Kornek B. Treatment of pediatric multiple sclerosis. Neuropediatrics. 2013;44(6):309-13doi: 10.1055/s-0033-1359308.
Kornek, B. (2013). Treatment of pediatric multiple sclerosis. Neuropediatrics, 44(6), 309-13. https://doi.org/10.1055/s-0033-1359308
Kornek, Barbara. "Treatment of pediatric multiple sclerosis." Neuropediatrics vol. 44,6 (2013): 309-13. doi: https://doi.org/10.1055/s-0033-1359308
Kornek B. Treatment of pediatric multiple sclerosis. Neuropediatrics. 2013 Dec;44(6):309-13. doi: 10.1055/s-0033-1359308. Epub 2013 Nov 07. PMID: 24203855.
Copy Download .nbib Format: NLM
Multiple sclerosis: From new concepts to updates on management.

Presse medicale (Paris, France : 1983)

Laplaud DA.
PMID: 25823830
Presse Med. 2015 Apr;44(4):e101-2. doi: 10.1016/j.lpm.2015.03.003. Epub 2015 Mar 29.

No abstract available.

Cite
Laplaud DA. Multiple sclerosis: From new concepts to updates on management. Presse Med. 2015;44(4):e101-2doi: 10.1016/j.lpm.2015.03.003.
Laplaud, D. A. (2015). Multiple sclerosis: From new concepts to updates on management. Presse medicale (Paris, France : 1983), 44(4), e101-2. https://doi.org/10.1016/j.lpm.2015.03.003
Laplaud, David-Axel. "Multiple sclerosis: From new concepts to updates on management." Presse medicale (Paris, France : 1983) vol. 44,4 (2015): e101-2. doi: https://doi.org/10.1016/j.lpm.2015.03.003
Laplaud DA. Multiple sclerosis: From new concepts to updates on management. Presse Med. 2015 Apr;44(4):e101-2. doi: 10.1016/j.lpm.2015.03.003. Epub 2015 Mar 29. PMID: 25823830.
Copy Download .nbib Format: NLM
MS patients must have access to the best treatment options.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)

Mitchell M.
PMID: 24823585
Nurs Stand. 2014 May 20;28(37):35. doi: 10.7748/ns.28.37.35.s40.

No abstract available.

Cite
Mitchell M. MS patients must have access to the best treatment options. Nurs Stand. 2014;28(37):35doi: 10.7748/ns.28.37.35.s40.
Mitchell, M. (2014). MS patients must have access to the best treatment options. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 28(37), 35. https://doi.org/10.7748/ns.28.37.35.s40
Mitchell, Michelle. "MS patients must have access to the best treatment options." Nursing standard (Royal College of Nursing (Great Britain) : 1987) vol. 28,37 (2014): 35. doi: https://doi.org/10.7748/ns.28.37.35.s40
Mitchell M. MS patients must have access to the best treatment options. Nurs Stand. 2014 May 20;28(37):35. doi: 10.7748/ns.28.37.35.s40. PMID: 24823585.
Copy Download .nbib Format: NLM
Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

Costello FE, Santos-Lang M.
PMID: 25768247
J Neuroophthalmol. 2015 Jun;35(2):e15-6. doi: 10.1097/WNO.0000000000000232.

No abstract available.

Cite
Costello FE, Santos-Lang M. Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). J Neuroophthalmol. 2015;35(2):e15-6doi: 10.1097/WNO.0000000000000232.
Costello, F. E., & Santos-Lang, M. (2015). Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 35(2), e15-6. https://doi.org/10.1097/WNO.0000000000000232
Costello, Fiona E, and Santos-Lang, Marechiel. "Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)." Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society vol. 35,2 (2015): e15-6. doi: https://doi.org/10.1097/WNO.0000000000000232
Costello FE, Santos-Lang M. Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). J Neuroophthalmol. 2015 Jun;35(2):e15-6. doi: 10.1097/WNO.0000000000000232. PMID: 25768247.
Copy Download .nbib Format: NLM
[Future challenges in multiple sclerosis].

Medicina clinica

Fernández Ó.
PMID: 25732950
Med Clin (Barc). 2014 Dec;143:44-7. doi: 10.1016/S0025-7753(15)30010-5.

Multiple sclerosis occurs in genetically susceptible individuals, in whom an unknown environmental factor triggers an immune response, giving rise to a chronic and disabling autoimmune disease. Currently, significant progress is being made in our knowledge of the frequency and...

Cite
Fernández Ó. Retos futuros de la esclerosis múltiple. [Future challenges in multiple sclerosis]. Med Clin (Barc). 2014;143:44-7doi: 10.1016/S0025-7753(15)30010-5.
Fernández, �. �. (2014). Retos futuros de la esclerosis múltiple. [Future challenges in multiple sclerosis]. Medicina clinica, 14344-7. https://doi.org/10.1016/S0025-7753(15)30010-5
Fernández, Óscar. "Retos futuros de la esclerosis múltiple." [Future challenges in multiple sclerosis]. Medicina clinica vol. 143 (2014): 44-7. doi: https://doi.org/10.1016/S0025-7753(15)30010-5
Fernández Ó. Retos futuros de la esclerosis múltiple. [Future challenges in multiple sclerosis]. Med Clin (Barc). 2014 Dec;143:44-7. doi: 10.1016/S0025-7753(15)30010-5. Spanish. PMID: 25732950.
Copy Download .nbib Format: NLM
Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge.

Expert opinion on pharmacotherapy

Paul F, Veauthier C.
PMID: 22424379
Expert Opin Pharmacother. 2012 Apr;13(6):791-3. doi: 10.1517/14656566.2012.667075. Epub 2012 Mar 19.

No abstract available.

Cite
Paul F, Veauthier C. Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge. Expert Opin Pharmacother. 2012;13(6):791-3doi: 10.1517/14656566.2012.667075.
Paul, F., & Veauthier, C. (2012). Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge. Expert opinion on pharmacotherapy, 13(6), 791-3. https://doi.org/10.1517/14656566.2012.667075
Paul, Friedemann, and Veauthier, Christian. "Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge." Expert opinion on pharmacotherapy vol. 13,6 (2012): 791-3. doi: https://doi.org/10.1517/14656566.2012.667075
Paul F, Veauthier C. Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge. Expert Opin Pharmacother. 2012 Apr;13(6):791-3. doi: 10.1517/14656566.2012.667075. Epub 2012 Mar 19. PMID: 22424379.
Copy Download .nbib Format: NLM
Quality of life reporting in multiple sclerosis clinical trials: enough quality?.

Multiple sclerosis (Houndmills, Basingstoke, England)

Solari A.
PMID: 23235774
Mult Scler. 2012 Dec;18(12):1668-9. doi: 10.1177/1352458512447595.

No abstract available.

Cite
Solari A. Quality of life reporting in multiple sclerosis clinical trials: enough quality?. Mult Scler. 2012;18(12):1668-9doi: 10.1177/1352458512447595.
Solari, A. (2012). Quality of life reporting in multiple sclerosis clinical trials: enough quality?. Multiple sclerosis (Houndmills, Basingstoke, England), 18(12), 1668-9. https://doi.org/10.1177/1352458512447595
Solari, Alessandra. "Quality of life reporting in multiple sclerosis clinical trials: enough quality?." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 18,12 (2012): 1668-9. doi: https://doi.org/10.1177/1352458512447595
Solari A. Quality of life reporting in multiple sclerosis clinical trials: enough quality?. Mult Scler. 2012 Dec;18(12):1668-9. doi: 10.1177/1352458512447595. PMID: 23235774.
Copy Download .nbib Format: NLM
Multiple Sclerosis: Eyes on the Future.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

Costello FE, Burton JM.
PMID: 29438264
J Neuroophthalmol. 2018 Mar;38(1):81-84. doi: 10.1097/WNO.0000000000000631.

No abstract available.

Cite
Costello FE, Burton JM. Multiple Sclerosis: Eyes on the Future. J Neuroophthalmol. 2018;38(1):81-84doi: 10.1097/WNO.0000000000000631.
Costello, F. E., & Burton, J. M. (2018). Multiple Sclerosis: Eyes on the Future. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 38(1), 81-84. https://doi.org/10.1097/WNO.0000000000000631
Costello, Fiona E, and Burton, Jodie M. "Multiple Sclerosis: Eyes on the Future." Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society vol. 38,1 (2018): 81-84. doi: https://doi.org/10.1097/WNO.0000000000000631
Costello FE, Burton JM. Multiple Sclerosis: Eyes on the Future. J Neuroophthalmol. 2018 Mar;38(1):81-84. doi: 10.1097/WNO.0000000000000631. PMID: 29438264.
Copy Download .nbib Format: NLM
Multiple Sclerosis in Children: Current and Emerging Concepts.

Seminars in neurology

Brenton JN, Kammeyer R, Gluck L, Schreiner T, Makhani N.
PMID: 32294785
Semin Neurol. 2020 Apr;40(2):192-200. doi: 10.1055/s-0040-1703000. Epub 2020 Apr 15.

Multiple sclerosis is being increasingly recognized and diagnosed in children. In the past several years, advances have been made in diagnosing multiple sclerosis in children, identifying new genetic and environmental risk factors, delineating underlying immunobiology, characterizing imaging findings, and...

Cite
Brenton JN, Kammeyer R, Gluck L, et al. Multiple Sclerosis in Children: Current and Emerging Concepts. Semin Neurol. 2020;40(2):192-200doi: 10.1055/s-0040-1703000.
Brenton, J. N., Kammeyer, R., Gluck, L., Schreiner, T., & Makhani, N. (2020). Multiple Sclerosis in Children: Current and Emerging Concepts. Seminars in neurology, 40(2), 192-200. https://doi.org/10.1055/s-0040-1703000
Brenton, J Nicholas, et al. "Multiple Sclerosis in Children: Current and Emerging Concepts." Seminars in neurology vol. 40,2 (2020): 192-200. doi: https://doi.org/10.1055/s-0040-1703000
Brenton JN, Kammeyer R, Gluck L, Schreiner T, Makhani N. Multiple Sclerosis in Children: Current and Emerging Concepts. Semin Neurol. 2020 Apr;40(2):192-200. doi: 10.1055/s-0040-1703000. Epub 2020 Apr 15. PMID: 32294785; PMCID: PMC8514113.
Copy Download .nbib Format: NLM
Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.

European neurology

Henze T, Rieckmann P, Toyka KV.
PMID: 16966832
Eur Neurol. 2006;56(2):78-105. doi: 10.1159/000095699. Epub 2006 Sep 08.

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of...

Cite
Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105doi: 10.1159/000095699.
Henze, T., Rieckmann, P., Toyka, K. V. (2006). Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. European neurology, 56(2), 78-105. https://doi.org/10.1159/000095699
Henze, T, et al. "Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society." European neurology vol. 56,2 (2006): 78-105. doi: https://doi.org/10.1159/000095699
Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105. doi: 10.1159/000095699. Epub 2006 Sep 08. PMID: 16966832.
Copy Download .nbib Format: NLM
Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.

Multiple sclerosis (Houndmills, Basingstoke, England)

Ryan JM, Fortune J, Stennett A, Kilbride C, Lavelle G, Hendrie W, DeSouza L, Abdul M, Brewin D, David L, Anokye N, Victor C, Norris M.
PMID: 31668138
Mult Scler. 2020 Dec;26(14):1907-1918. doi: 10.1177/1352458519886231. Epub 2019 Oct 31.

BACKGROUND: There is limited information regarding the safety, feasibility and acceptability of behaviour-change interventions to increase physical activity (PA) and reduce sedentary behaviour among people with multiple sclerosis (MS). Prior to evaluating efficacy, it is important to identify problems...

Cite
Ryan JM, Fortune J, Stennett A, et al. Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial. Mult Scler. 2019;26(14):1907-1918doi: 10.1177/1352458519886231.
Ryan, J. M., Fortune, J., Stennett, A., Kilbride, C., Lavelle, G., Hendrie, W., DeSouza, L., Abdul, M., Brewin, D., David, L., Anokye, N., Victor, C., & Norris, M. (2020). Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial. Multiple sclerosis (Houndmills, Basingstoke, England), 26(14), 1907-1918. https://doi.org/10.1177/1352458519886231
Ryan, Jennifer M, et al. "Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 26,14 (2020): 1907-1918. doi: https://doi.org/10.1177/1352458519886231
Ryan JM, Fortune J, Stennett A, Kilbride C, Lavelle G, Hendrie W, DeSouza L, Abdul M, Brewin D, David L, Anokye N, Victor C, Norris M. Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial. Mult Scler. 2020 Dec;26(14):1907-1918. doi: 10.1177/1352458519886231. Epub 2019 Oct 31. PMID: 31668138.
Copy Download .nbib Format: NLM
COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register.

Multiple sclerosis and related disorders

Middleton RM, Craig EM, Rodgers WJ, Tuite-Dalton K, Garjani A, Evangelou N, das Nair R, Hunter R, Tallantyre EC, Cauchi M, Cairn C, Paling D, Fuller S, McDonnell G, Petheram K, Liu B, Nock U, Ingram G, Brownlee W, Taylor J, Nicholas R.
PMID: 34653949
Mult Scler Relat Disord. 2021 Nov;56:103317. doi: 10.1016/j.msard.2021.103317. Epub 2021 Oct 08.

BACKGROUND: In March 2020, the United Kingdom Multiple Sclerosis Register (UKMSR) established an electronic case return form, designed collaboratively by MS neurologists, to record data about COVID-19 infections in people with MS (pwMS).OBJECTIVES: Examine how hospital admission and mortality...

Cite
Middleton RM, Craig EM, Rodgers WJ, et al. COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register. Mult Scler Relat Disord. 2021;56:103317doi: 10.1016/j.msard.2021.103317.
Middleton, R. M., Craig, E. M., Rodgers, W. J., Tuite-Dalton, K., Garjani, A., Evangelou, N., das Nair, R., Hunter, R., Tallantyre, E. C., Cauchi, M., Cairn, C., Paling, D., Fuller, S., McDonnell, G., Petheram, K., Liu, B., Nock, U., Ingram, G., Brownlee, W., Taylor, J., Nicholas, R. (2021). COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple sclerosis and related disorders, 56103317. https://doi.org/10.1016/j.msard.2021.103317
Middleton, R M, et al. "COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register." Multiple sclerosis and related disorders vol. 56 (2021): 103317. doi: https://doi.org/10.1016/j.msard.2021.103317
Middleton RM, Craig EM, Rodgers WJ, Tuite-Dalton K, Garjani A, Evangelou N, das Nair R, Hunter R, Tallantyre EC, Cauchi M, Cairn C, Paling D, Fuller S, McDonnell G, Petheram K, Liu B, Nock U, Ingram G, Brownlee W, Taylor J, Nicholas R. COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register. Mult Scler Relat Disord. 2021 Nov;56:103317. doi: 10.1016/j.msard.2021.103317. Epub 2021 Oct 08. PMID: 34653949.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 128 entries